biostudies-literatureChan DRobert A. and Renee E. Belfer Family FoundationAlan AldaNCATS NIH HHSNICHD NIH HHSNIA NIH HHSGary Hua and Li ChenCharles HiekenDonald A. and Glenda G. MattesAlan and Susan PatricofJoseph P. DiSabato and Nancy E. SakamotoDavid B EmmesNINDS NIH HHSJBP FoundationNIDA NIH HHSEleanor Schwartz Charitable FoundationJay L. and Carroll D. MillerPicower FellowshipNIH Loan Repayment ProgramDegroof-VM FoundationElizabeth K. and Russell L. SiegelmanLester GimpelsonDoris Duke Charitable FoundationLudwig Family FoundationHarvard CatalystKo Hahn FamilyMarc Haas FoundationDave Wargoe0278412https://www.ebi.ac.uk/biostudies/studies/S-EPMC9714926biostudies-literatureUnknown17(12)Non-invasive Gamma ENtrainment Using Sensory stimulation (GENUS) at 40Hz reduces Alzheimer's disease (AD) pathology such as amyloid and tau levels, prevents cerebral atrophy, and improves behavioral testing performance in mouse models of AD. Here, we report data from (1) a Phase 1 feasibility study (NCT04042922, ClinicalTrials.gov) in cognitively normal volunteers (n = 25), patients with mild AD dementia (n = 16), and patients with epilepsy who underwent intracranial electrode monitoring (n = 2) to assess safety and feasibility of a single brief GENUS session to induce entrainment and (2) a single-blinded, randomized, placebo-controlled Phase 2A pilot study (NCT04055376) in patients with mild probable AD dementia (n = 15) to assess safety, compliance, entrainment, and exploratory clinical PloS oneGamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies.PMC9714926UDIW8172R01 HD107064U54 AG062322P50 HD103556UL1 TR002541R01 NS11452615367R21 DA052861R01 NS099055U01 NS114001Uitermarkt BBoes ADKitchener EBeach SDNieto-Castanon ABanerjee ABrown ENStearns CSternberg EJWhitfield-Gabrieli SJackson BLHoward MKlerman EBGander PAnteraper SSuk HJMilman NPChan DDickerson BCBlanchard JFernandez Avalos VSde Weck GBoyden ESTsai LHStark DfalseGamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies.Non-invasive Gamma ENtrainment Using Sensory stimulation (GENUS) at 40Hz reduces Alzheimer's disease (AD) pathology such as amyloid and tau levels, prevents cerebral atrophy, and improves behavioral testing performance in mouse models of AD. Here, we report data from (1) a Phase 1 feasibility study (NCT04042922, ClinicalTrials.gov) in cognitively normal volunteers (n = 25), patients with mild AD dementia (n = 16), and patients with epilepsy who underwent intracranial electrode monitoring (n = 2) to assess safety and feasibility of a single brief GENUS session to induce entrainment and (2) a single-blinded, randomized, placebo-controlled Phase 2A pilot study (NCT04055376) in patients with mild probable AD dementia (n = 15) to assess safety, compliance, entrainment, and exploratory clinical 2022-01-01T00:00:00Z20222026-05-28T06:50:59.986Z2025-04-07T06:25:16.247ZS-EPMC97149263645496910.1371/journal.pone.0278412